What is Vertex Pharmaceuticals's pre-tax income (domestic)?

Vertex Pharmaceuticals (VRTX) reported pre-tax income (domestic) of $705.3M in Q4 2025.

How has Vertex Pharmaceuticals's pre-tax income (domestic) changed year-over-year?

Vertex Pharmaceuticals's pre-tax income (domestic) increased by 306.0% year-over-year, from -$342.43M to $705.3M.

What is the long-term trend for Vertex Pharmaceuticals's pre-tax income (domestic)?

Over 2 years (2023 to 2025), Vertex Pharmaceuticals's pre-tax income (domestic) has grown at a -4.4% compound annual growth rate (CAGR), from $3.09B to $2.82B.

Vertex Pharmaceuticals VRTX Pre-Tax Income (Domestic)

Pre-Tax Income (Domestic) at other companies

Jazz PharmaceuticalsJAZZ

$41.17M-66.9%

Other financials

Income statement

See full

Revenue$3.0B+7.8%

Gross profit$2.6B+7.8%

Operating income$1.1B+80.6%

Net income$1.0B+59.6%

EPS (diluted)$4.02+61.4%

Balance sheet

See full

Cash & equivalents$5.5B+17.5%

Total debt$2.0B+20.5%

Total equity$19.4B+17.4%

Total assets$26.5B+15.8%

Cash flow

See full

Operating cash flow$1.4B+74.4%

CapEx$133.4M+228%

Free cash flow$1.3B+66.4%

Valuation

See full

Market cap$114.63B-8.9%

Enterprise value$111.11B-9.5%

P/E26.4×—

P/S9.4×-2.0×

Profitability

See full

Gross margin86.2%+0.2pp

Operating margin38.3%—

Net margin35.5%—

FCF margin30.4%+20.2pp

Returns & leverage

See full

Return on equity24.2%—

Debt / equity0.1×0.0×

Current ratio3×+0.4×

Where this comes from

Reported directly by Vertex Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic.

The official record: Vertex Pharmaceuticals’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vertex Pharmaceuticals's pre-tax income (domestic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vertex Pharmaceuticals's pre-tax income (domestic)?: Vertex Pharmaceuticals (VRTX) reported pre-tax income (domestic) of $705.3M in Q4 2025.
How has Vertex Pharmaceuticals's pre-tax income (domestic) changed year-over-year?: Vertex Pharmaceuticals's pre-tax income (domestic) increased by 306.0% year-over-year, from -$342.43M to $705.3M.
What is the long-term trend for Vertex Pharmaceuticals's pre-tax income (domestic)?: Over 2 years (2023 to 2025), Vertex Pharmaceuticals's pre-tax income (domestic) has grown at a -4.4% compound annual growth rate (CAGR), from $3.09B to $2.82B.